Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activities in the elevated T-maze

Pharmacology Biochemistry and Behavior

Volumn 110, Issue , 2013, Pages 33-39

  Gobira, Pedro H ^a   Aguiar, Daniele C ^a   Moreira, Fabrício A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anandamide; Animal models; Anxiety; Cannabinoids; Panic

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ALPRAZOLAM; ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DIAZEPAM; ENDOCANNABINOID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ESCAPE BEHAVIOR; LOCOMOTION; MALE; MAZE TEST; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA; RATTUS;

ANANDAMIDE; ANIMAL MODELS; ANXIETY; CANNABINOIDS; PANIC;

ALPRAZOLAM; ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BENZAMIDES; BENZODIAZEPINES; BENZOXAZINES; CARBAMATES; ENDOCANNABINOIDS; LOCOMOTION; MALE; MAZE LEARNING; MORPHOLINES; NAPHTHALENES; PANIC; PIPERIDINES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1;

EID: 84879475262     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.05.013     Document Type: Article

References (44)

1. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 2002;163: 111-7. (Pubitemid 34985320)
2. BortolatoM, Campolongo P, Mangieri RA, ScattoniML, Frau R, Trezza V, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 2006;31: 2652-9. (Pubitemid 44764162)
3. Casarotto PC, Terzian AL, Aguiar DC, Zangrossi H, Guimaraes FS, Wotjak CT, et al. Opposing roles for cannabinoid receptor type-1 (CB) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats. Neuropsychopharmacology 2012;37: 478-86.
4. de Bortoli VC, Nogueira RL, Zangrossi Jr H. Alprazolam potentiates the antiaversive effect induced by the activation of 5-HT(1A) and 5-HT (2A) receptors in the rat dorsal periaqueductal gray. Psychopharmacology (Berl) 2008;198: 341-9.
5. de Paula Soares V, Zangrossi Jr H. Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats. Behav Brain Res 2009;197: 178-85.
6. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7: 438-55. (Pubitemid 351649182)
7. Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA, et al. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 2003;45: 594-604. (Pubitemid 36980816)
8. Graeff FG, Viana MB, Tomaz C. The elevated T maze, a new experimentalmodel of anxiety and memory: effect of diazepam. Braz J Med Biol Res 1993;26: 67-70. (Pubitemid 23109339)
9. Graeff FG, Netto CF, Zangrossi Jr H. The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 1998;23: 237-46. (Pubitemid 29011625)
10. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002;16: 1395-8. (Pubitemid 35340861)
11. Haller J, Varga B, Ledent C, Freund TF. CB1 cannabinoid receptorsmediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004;15: 299-304. (Pubitemid 39062560)
12. Hill MN, Gorzalka BB. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur J Pharmacol 2004;499: 291-5. (Pubitemid 39233668)
13. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54: 161-202. (Pubitemid 34575709)
14. Iversen L. Cannabis and the brain. Brain 2003;126: 1252-70. (Pubitemid 36644373)
15. Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, et al. A key role for orexin in panic anxiety. Nat Med 2010;16: 111-5.
16. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9: 76-81. (Pubitemid 36098263)
17. Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 2012;35: 529-58.
18. Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 2011;13: 423-37.
19. Lafenetre P, Chaouloff F, Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 2007;56: 367-81. (Pubitemid 350026395)
20. Leweke FM, Schneider M. Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. Int J Neuropsychopharmacol 2011;14: 43-51.
21. Marco EM, Garcia-Gutierrez MS, Bermudez-Silva FJ, Moreira FA, Guimaraes F, Manzanares J, et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci 2011;5:63.
22. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002;159: 379-87. (Pubitemid 34143362)
23. Moreira FA, Wotjak CT. Cannabinoids and anxiety. Curr Top Behav Neurosci 2010;2: 429-50.
24. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 2007;52: 958-65. (Pubitemid 46227483)
25. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid- degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008;54: 141-50. (Pubitemid 350299416)
26. Moreira FA, Aguiar DC, Campos AC, Lisboa SF, Terzian AL, Resstel LB, et al. Antiaversive effects of cannabinoids: is the periaqueductal gray involved? Neural Plast 2009;2009: 625469.
27. Moreira FA, AguiarDC, Terzian AL, Guimaraes FS, Wotjak CT. Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin? Neuroscience 2012;204: 186-92.
28. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005;10: 49-56. (Pubitemid 40139743)
29. Pamplona F, Takahashi R. Psychopharmacology of the endocannabinoids: far beyond anandamide. J Psychopharmacol 2012;26: 7-22.
30. Parolaro D, Realini N, Vigano D, Guidali C, Rubino T. The endocannabinoid system and psychiatric disorders. Exp Neurol 2010;224: 3-14.
31. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006;318: 304-11.
32. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985;14: 149-67. (Pubitemid 16239568)
33. Pinheiro SH, Zangrossi Jr H, Del-Ben CM, Graeff FG. Elevated mazes as animal models of anxiety: effects of serotonergic agents. An Acad Bras Cienc 2007;79: 71-85. (Pubitemid 46516260)
34. Poltronieri SC, Zangrossi Jr H, de Barros Viana M. Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behav Brain Res 2003;147: 185-92. (Pubitemid 37491426)
35. Rey AA, Purrio M, Viveros MP, Lutz B. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 2012;37: 2624-34.
36. Rodgers RJ, Evans PM, Murphy A. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 2005;16: 405-13. (Pubitemid 41404812)
37. Rubino T, SalaM, ViganoD, BraidaD, Castiglioni C, Limonta V, et al. Cellularmechanisms underlying the anxiolytic effect of lowdoses of peripheral delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology 2007;32: 2036-45. (Pubitemid 47258523)
38. Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, et al. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 2010;20: 112-22.
39. Takahashi RN, Pamplona FA, Fernandes MS. The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 2005;380: 270-5. (Pubitemid 40616094)
40. Teixeira RC, Zangrossi H, Graeff FG. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol Biochem Behav 2000;65: 571-6. (Pubitemid 30182498)
41. Thiemann G, Watt CA, Ledent C, Molleman A, Hasenohrl RU. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor inmice together with biogenic amine changes in the forebrain. Behav Brain Res 2009;200: 60-7.
42. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005;81: 331-42. (Pubitemid 40807131)
43. Viveros MP, Marco EM, Llorente R, Lopez-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007;2007:52908.
44. Zangrossi Jr H, Graeff FG. Behavioral validation of the elevated T-maze, a new animal model of anxiety. Brain Res Bull 1997;44: 1-5. (Pubitemid 27375172)